NRIX
NASDAQNurix Therapeutics Inc.
Price$14.65-1.61 (-9.90%)
2026-03-042026-06-05
News · 26 weeks58-86%
2025-12-142026-06-07
Mix3390d
- Insider16(48%)
- Other10(30%)
- SEC Filings5(15%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- PRRoche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurologyAgreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of
- PRNurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyStrategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milesto
- INSIDERChief Legal Officer Ring Christine exercised 3,422 shares at a strike of $1.86 and sold $135,253 worth of shares (8,148 units at $16.60) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 13,579 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Director Silva Paul M4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Director Saltzman Edward C4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Director Reinsdorf Judith A4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Nurix Therapeutics Inc.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Nurix Therapeutics Inc.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Director Dansey Roger D4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Director Baynes Roy D.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERSEC Form 4 filed by Director Gregory Julia P4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SECNurix Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
- PRNurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual MeetingIn preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK degradation in blood and skin Phase 1 studies support continued exploration of new tablet formulation in inflammation and immunology indications BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the
- PRNurix Therapeutics to Participate in Upcoming Investor ConferencesBRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences: RBC Global Healthcare ConferenceWednesday, May 20, 2026, at 1:30 p.m. ET. Jefferies Global Healthcare ConferenceWednesday, June 3, 2026, at 11:05 a.m. ET. The fireside chats will be webcast live and may be viewed via a link in the Investors section
- PRNurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association CongressBRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Oral Presentation Details: Title: Updated efficacy and safety data
- SECSEC Form SCHEDULE 13G filed by Nurix Therapeutics Inc.SCHEDULE 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
- INSIDERChief Financial Officer Van Houte Hans sold $233,319 worth of shares (14,055 units at $16.60) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 37,592 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Legal Officer Ring Christine sold $138,210 worth of shares (8,148 units at $16.96) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 18,305 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Legal Officer Ring Christine sold $90,407 worth of shares (5,394 units at $16.76) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 26,453 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Financial Officer Van Houte Hans converted options into 8,608 shares and sold $39,749 worth of shares (2,388 units at $16.65), increasing direct ownership by 14% to 51,647 units (SEC Form 4) to satisfy withholding tax4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Legal Officer Ring Christine converted options into 8,608 shares and sold $53,498 worth of shares (3,214 units at $16.65), increasing direct ownership by 20% to 31,847 units (SEC Form 4) (for tax liability)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Scientific Officer Hansen Gwenn converted options into 8,608 shares and sold $53,498 worth of shares (3,214 units at $16.65), increasing direct ownership by 5% to 120,399 units (SEC Form 4) to satisfy withholding obligation4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
- PRNurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach Featured AACR Advances session underscores Nurix's scientific leadership in targeted protein degradation and induced proximity pharmacology BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, today announced new preclinical data from multiple oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2026. The pres
- SECSEC Form 10-Q filed by Nurix Therapeutics Inc.10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
NRIX FAQ
7 questionsWhat does Nurix Therapeutics Inc. do?
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma...Where does NRIX stock trade?
Nurix Therapeutics Inc. (NRIX) is listed on NASDAQ.What sector and industry is NRIX in?
Nurix Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nurix Therapeutics Inc. go public?
Nurix Therapeutics Inc. (NRIX) completed its IPO in 2020.What are analysts saying about NRIX?
Nurix Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight with a $3600.00 price target on 2026-01-08. Recent price targets range from $1600.00 to $4100.00.What companies are similar to NRIX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NRIX side-by-side with any of them on Quantisnow.How can I track NRIX on Quantisnow?
Quantisnow aggregates Nurix Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRIX to receive live email and push alerts on every new disclosure.